Pharmamarketeer

EMA begins evaluating use of RoActemra in hospitalised adults with severe Covid-19

EMA has started evaluating the anti─inflammatory medicine RoActemra (tocilizumab) to extend its use to include treatment of hospitalised adult patients with severe Covid─19 who are already receiving treatment with corticosteroids and require extra oxygen or mechanical ventilation

Medhc-fases-banner
Advertentie(s)